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807-5 A Multicenter Study of the Safety and Efficacy of 
Disopyramide for Treating Symptomatic Obstructive 
Hypertrophic Cardiomyopathy 
Mark Sherrid Ivan Barac, Barry Maron, Susan Casey, Lidia Chojnowska, Shaughan -1 
Dickie, Perry Elliott, William McKenna, St. Luke’sRoosevelt Hospital Center, New York 
City, NY 
Background: Disopyramide (diso) has been shown to reduce gradient and improve 
symptoms in patients (pts) with obstructive hyperlrophic cardiomyopathy (HCM). It is 
often administered to medically refractory pts who would otherwise next require septal 
myectomy or other interventions. However, the clinical course of HCM pts treated with 
diso has never been investigated in a large cohort. Methods: 141 pts with HCM were 
treated with diso at 4 treatment centers from 1990 to 1999. Resting echo gradient and 
NYHA class were compared before diso and at follow-up on medication. Results: 141 
pts (mean age 46.6) were treated with diso for a mean of 3.9 years with a mean highest 
dose of 426 + 180 mg/day. Most recent gradient on diso was 45 + 34 mm Hg, signifi- 
cantly lower than baseline gradient 78 -+ 35 mm Hg, a 42% reduction, p>O.OOOl. 74% of 
pts had > 15 mm Hg reduction in gradient, and 42% had > 40% reduction. NYHA class 
improved on drug, 16165/28/Z to 36/57/18/O for classes I, II, Ill, IV respectively, p>O.Ol. 
Also, the percentage of patients in NYHA class Ill and IV decreased after diso from 27% 
to 16%, p=O.O5. There were 4 HCM-related sudden cardiac deaths that occurred on diso, 
occurring mean 54 months after initial administration of diso. Annual rate of HCM-related 
sudden cardiac death was 0.88% and annual rate of all-cause cardiac death was 1.29%. 
Mortality on diso did not differ from that in 5 separate published series of HCM pts each 
with a250 patients published from 1998-2001 where annual rate of sudden cardiac death 
ranged from 0.74-1.13%, ~~0.47 and annual rate of all-cause cardiac death. ranged from 
1.22-I .78%. p=O.l8. 93 pts (88%) were still on diso at follow-up. The majority of pts could 
be managed without myectomy or other intervention; but, while taking diso 32% ulti- 
mately required intervention for relief of obstruction. Conclusions: Patients with HCM 
treated with disopyramide showed a significant and persistent decrease in outilow gradi- 
ent of 42% and improvement in limiting symptoms. No excess sudden cardiac death 
occurred. A therapeutic trial of disopyramide should be considered before proceeding to 
major intervention in obstructive HCM. 
ORAL CONTRIBUTIONS 
809 Molecular Mechanism of Ventricular 
Remodeling 
Monday, March 31, 2003, 9:15 a.m.-lo:30 a.m. 
McCormick Place, Room S405 
9:15 a.m. 
809-l Early Postinfarction Ventricular Restraint Prevents 
Adverse Remodeling and Preserves Borderzone 
Contractile Function 
Beniamin M. Jackson, Joseph H. German, Ill, Sina L. Moainie, Navneet Narula, Jagat 
Narula, Martin G. St. John Sutton, L. H. Edmunds, Jr., Robert C. German, Hospital of the 
University of Pennsylvania, Philadelphia, PA, Hahnemann University Hospital, 
Philadelphia, PA 
Background: Postinfarction ventricular remodeling is the major cause of CHF. Early inf- 
arct expansion (stretching) initiates adverse remodeling and progressive contractile dys- 
function in normally-perfused borderzone (BZ) myocardium. Early LV restraint may 
prevent this maladaptive phenomenon. 
Methods: An infarction of 20% of the LV mass known to cause CHF and LV dilatation in 
8 weeks was performed in 12 sheep. In six sheep Merselme mash was wrapped around 
the exposed LV (excluding septum and RV) at the time of infarction. Six sheep acted as 
controls. LV remodeling, diastolic function, regional contractility and perfusion were 
assessed by echocardiography, sonomicrometry and microsphere injections, respec- 
tively, over 8 weeks. 
m: The control group experienced progressive LV dilatation, expansion of the aki- 
netic segment and progressive borderzone contractile dysfunction. Infarct expansion, LV 
dilatation and borderzone contractile dysfunction were prevented or significantly reduced 
in the animals having early postinfarction LV wrapping. Myocardial perfusion was 
unchanged in the uninfarcted regions in all animals. There was no evidence of wrap- 
induced diastolic dysfunction. 
Conclusion : Early postinfarction ventricular restraint to prevent infarct expansion pre- 
vents adverse remodelino and preserves contractile function in non-infarcted myocar- 
dium. 
(^ pcO.05 preinfarct vs. postinfarct, 
mined immediately after infarction) 
+ pco.05 wrap vs. control, ** “Preinfarct” value deter- 
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809-2 Matrix Metalloproteinase Inhibition In Transgenic Mice 
With Modified Cardiac Restricted Tumor Necrosis 
Factor Expression: Effects on Lefl Ventricular 
Geometry and Function 
Abhinav Diwan, Eric M. Wilson, Andrea M. Parkhurst, Patricia Escobar, Jennifer W. 
Hendrik, Kathryn B. Dowdy, Abigail S. Lowry, Jennifer R. Holder, Dorellyn Lee-Jackson, 
Francis G. Spinale, Douglas L. Mann, Baylor College of Medicine, Houston. TX, Medical 
University of South Carolina, Charleston, SC 
Background: Matrix metalloproteinases contribute to adverse left ventricular (LV) 
remodeling and are influenced by tumor necrosis factor (TNF) signaling: however, a 
causal relationship remains to be established. We examined the effects of matrix metal- 
loprotelnase inhibition (MMPi) on LV geometry and function in 2 lines of transgenic mice 
with myocardial overexpression of (I) secreted TNF (sTNF) that develop LV dilation, (2) 
a non-cleavable membrane bound form of TNF (mTNF), that develop concentric LV 
hypertrophy. 
Methods: MMPi (PD166793 30mg/kg/day) was instituted from 3 to 6 weeks of age in 
sTNF (n=l3) and mTNF (n=7) mice. Untreated 6 week old wild type (n=l3), sTNF (n=ll) 
and mTNF (n=8) mice served as conlrols. LV end-diastolic volume and ejection fraction 
were determined by conductance volumetry and contractility assessed by computing 
E,,, with caval occlusion. 
Results: (Table: ‘peO.05 vs wild type, tvs mTNF, #vs sTNF). LV end-diastolic volume 
was increased in the sTNF group and was reduced with MMPi. MMPi increased LV ejec- 
tion fraction in both the sTNF and mTNF groups, likely due in part to increased E,,,. LV 
hypertrophy was unaffected by MMPi. 
Conclusions: MMPi reduced the amount of LV dilation in the sTNF mice, suggesting 
that MMP-induced alterations in the extracellular matrix influence myocardial structure 
(dilation). MMPi resulted in an increase in contractile function in fhe mTNF and sTNF 
mice, suggesting that MMP-induced alterations in the extracellular matrix influence myo- 
cardial function. 
Results : All values are Mean * SEM 
Wild mTNF mTNF+M sTNF sTNF+M 
Type MPi MPi 
End-Diastolic Volume (pL) 39*2 42~4 36*3 81+4’ 49*4’# 
t 
Ejection Fraction (%) 66*1 66*2 73il *t 68*2 7l+l’t 
E,,,,, (Maximal Chamber Elasticity, 5.3i0.8 5.1~1. 11.3*1.4” 5.3+1. 10.4*2.2’ 
mmHg/@) 3 t 3 # 
LV Mass/Tibia (mg/mm) 5.8kO.3 8.2+0. 8.3eO.4 8.6&O. 7.8eO.5’ 
3’ 3 
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809-3 Testosterone Aggravates Cardiac Performance and 
Remodeling in Mice After Myocardial Infarction 
Maria A. Cavasin, Ai-Li Yu, Shreevidya Menon, Xiao-Ping Yang, Henry Ford Health 
System, Detroit, MI 
The cardioprotective effects of estrogen have been widely studied. However, little is 
known about the effects of testosterone (T) on chronic remodeling and prognosis after 
Ml. We found that female mice given supplemental T had significantly higher mortality 
(due lo cardiac rupture) than those treated with placebo (P) during the first week after Ml 
regardless of ovariectomy. whereas castration significantly reduced mortality in males. 
We hypothesized that testosterone may aggravate chronic cardiac remodeling and dys- 
function, whereas estrogen may be cardioprotective after Ml. 4.week-old males and 
females underwent either castration (cas), or sham castration (s-cas), and ovariectomy 
(ovx) or sham ovariectomy (s-ovx). respectevely. S-ovx females were treated with either 
